Research Papers:

A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival

Sara Massironi _, Roberta Elisa Rossi, Alessandra Zilli, Giovanni Casazza, Clorinda Ciafardini and Dario Conte

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:18978-18983. https://doi.org/10.18632/oncotarget.7902

Metrics: PDF 744 views  |   HTML 1106 views  |   ?  


Sara Massironi1, Roberta Elisa Rossi1,2, Alessandra Zilli1,2, Giovanni Casazza3, Clorinda Ciafardini1, Dario Conte1,2

1Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

2Postgraduate School of Gastroenterology, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

3Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, Milan, Italy

Correspondence to:

Sara Massironi, email: sara.massironi@policlinico.mi.it

Keywords: pancreatic neuroendocrine neoplasms, neuroendocrine tumors, pNEN, non-functional pancreatic neuroendocrine tumors

Received: December 22, 2015     Accepted: February 11, 2016     Published: March 3, 2016


Background: Whether all the small (ø≤20mm) non-functional pancreatic neuroendocrine neoplasms (pNENs) should be routinely resected is unclear.

Aim: To assess the overall survival (OS) and progression-free survival (PFS) of patients with small pNENs, followed-up with different management options.

Material and methods: Between 2007-2014, 51 patients were newly diagnosed with pNEN. 15 patients with pNENs ø ≤20 mm underwent an intensive follow-up at 3-month intervals during the first year and then every 6 months (FU pNEN group). They were all at TNM stage I, except for one patient at stage IIA. 21 patients underwent surgical resection (SR pNEN group): 2 patients were at TNM stage I, 9 IIA, one IIIB, 9 IV. 15 patients received systemic therapy (ST pNEN group) due to advanced disease or contraindications to surgery: 5 were at stage IIA, 2 IIB, 8 IV.

Results: The median follow-up for the entire cohort was 50 months. Survival was similar in the FU and SR pNEN groups, but significantly worst in the ST pNEN patients (log-rank test P <0.05). The 4-year survival rate was 100% in the FU pNEN group, 90.5% among the SR pNEN patients, 61% for the ST pNEN ones (p <0.0001). The disease remained stable in all but one patient in the FU pNEN group, whereas six patients in the SR group and five in the ST group showed disease progression.

Conclusions: The “wait-and-watch” approach to early-stage small pNENs appears to be safe although further studies are needed to confirm these results in larger cohorts of patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7902